Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757429 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL29814033 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL23363349 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL24805830 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL25971609 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAFAAHCYP2C19HTT | |
| SCHEMBL2363024 | 0.83 | GABRA1 (0.43) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL950804 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAFAAHCYP2C19HTT | |
| SCHEMBL30865552 | 0.79 | P2RX7 (0.42) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL1266671 | 0.79 | CYP2D6 (0.48) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 | |
| SCHEMBL27736338 | 0.79 | P2RX7 (0.42) | SMN1; SMN2LMNACYP2D6HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4076452-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| WO-2011005759-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005759-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | SMN1; SMN2 118/4885LMNA 680/4885CYP2D6 996/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | SMN1; SMN2 4739/4885LMNA 3566/4885CYP2D6 3639/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885CYP2D6 2839/4885 |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | SMN1; SMN2 4659/4885LMNA 1162/4885CYP2D6 4085/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 349/4885LMNA 1841/4885CYP2D6 1074/4885 |
| US-12583871-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 90/4885LMNA 1554/4885CYP2D6 1260/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | SMN1; SMN2 2767/4885LMNA 1435/4885CYP2D6 1707/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | SMN1; SMN2 3533/4885LMNA 1393/4885CYP2D6 580/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | SMN1; SMN2 4659/4885LMNA 1162/4885CYP2D6 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.